Long-term remission of schizophrenia in an adolescent treated with quetiapine

Journal of Child and Adolescent Psychopharmacology

Volumn 11, Issue 3, 2001, Pages 289-293

  Hayden, F ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ARTICLE; BRADYKINESIA; CASE REPORT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LETHARGY; REMISSION; SCHIZOPHRENIA; SEDATION; WEIGHT GAIN;

EID: 0034786474     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/10445460152595612     Document Type: Article

References (16)

1. Antipsychotics in children and adolescents
2. Review of quetiapine side effects
3. Teenage psychosis: Epidemiology, classification, and reduced optimality in the pre-, peri- and neonatal periods
4. Comparative side effects of atypical neuroleptics in children and adolescents
5. Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia?
6. Quetiapine in adolescent psychosis
7. A summary of research findings on the new antipsychotic drugs
8. Commentary on the clozapine conflict
9. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders
10. Preclinical pharmacology of neuroleptics: Focus on new generation compounds
11. Attentional improvement following quetiapine fumarate treatment in schizophrenia
12. Treatment and outcomes in adolescents with schizophrenia
13. Quetiapine for refractory schizophrenia
14. Newer atypical antipsychotic medication versus clozapine for schizophrenia. (Cochrane Review)